Landos Prices $ 100 Million IPO RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by its portfolio company Landos Biopharma, Inc. ( Landos ) on 03 February 2021 of its pricing of a $ 100 million initial public offering ( IPO ) and admission to trade on Nasdaq Global Market under ticker LABP . Landos is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral therapeutics for patients with autoimmune diseases. The lead asset BT-11 is a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn s disease that targets the LANCL2 pathway.
Landos Biopharma Announces Pricing of Initial Public Offering
February 03, 2021 20:13 ET | Source: Landos Biopharma, Inc. Landos Biopharma, Inc. Blacksburg, Virginia, UNITED STATES
BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.